Centessa Pharmaceuticals plc (CNTA) has priced its underwritten public offering of 11.63 million American Depositary Shares ("ADSs"), each representing one ordinary share, at $21.50 per ADS.
This clinical-stage biopharmaceutical company is pioneering a new class of therapies targeting orexin receptor 2 (OX2R) for neurological, neurodegenerative, and neuropsychiatric disorders.
The offering, which is scheduled to close on or about November 14, 2025, is expected to generate gross proceeds of approximately $250 million before deducting underwriting discounts and expenses.
The underwriters have a 30-day option to purchase up to an additional 1.74 million ADSs at the public offering price, less underwriting discounts and commissions.
CNTA has traded in the range of $9.60 - $25.42 in the last 1 year. The stock closed yesterday's trading at $22.54, up 0.94%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.